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ABSTRACT
The biopharmaceutical industry uses recombinant protein technologies to provide novel
therapeutics to patients around the world. These technologies have presented exciting
opportunities for breakthrough medical treatments while creating a host of challenges in the
discovery, development and manufacture of these products. Protein aggregation is one of the
challenges currently limiting the ability to bring new biopharmaceutical products into the market
and to manufacture existing commercial products. The mechanisms of aggregation andi
subsequent particle formation are highly complex, incompletely understood, and difficult to
measure quantitatively with currently available analytical tools. Aggregates, and their effect on
product appearance, may compromise value to the patient (bioavailability, dose, therapeutic
activity and immunogenicity) as well as value to the company (yield loss and performance in a
competitive marketplace) and are therefore tightly regulated.
This thesis is intended to explore the problem of protein particles through two main avenues:
meeting current regulatory criteria and influencing future regulation. Process changes, analytical
characterization, and organizational improvements are each addressed to achieve that goal. An
experiment was designed and completed to jointly examine (1) changes to manufacturing
processes using novel filtration applications intended to reduce or remove protein particles from
solution and (2) analytical tools for improved characterization. Organizational dynamics and
resource allocation add an extra layer of complexity and are discussed in relation to leveraging
knowledge regarding particles. Additionally, three objectives are established to influence the
direction of future regulation: the need for improved characterization, industry collaboration and
a healthy interface with regulatory bodies.
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1. Introduction
Biotechnological medicines, first introduced in 1982, were expected to revolutionize the
pharmaceutical industry. With a lower toxicity and a more predictable behavior in vivo, these
medicines could potentially reach the market faster and benefit more patients than the traditional
chemical entities available at the time. However, the advent of new technologies brought with it
a host of novel challenges that curb the rate of industry growth.
Up to 96% of all drug candidates in trials are abandoned during preclinical or clinical
development, often because of low solubility or intrinsic propensity to aggregate irreversibly
(Caldwell, 2001, Chi, 2003). Irreversible aggregation presents one of the most difficult obstacles
in the development of high concentration protein therapeutics due to a lack of clear
understanding of the protein aggregation mechanistic process and the potential safety impact of
protein particles. Aggregates and their effect on product appearance may compromise value to
the patient (bioavailability, dose, therapeutic activity and immunogenicity) as well as value to the
company (performance in a competitive marketplace). Since it is the paramount responsibility of
biotech companies and regulatory bodies to provide the best guarantee of safety and efficacy to
patients, the problems surrounding protein aggregation must be better understood. To achieve
that end, academic institutions, biotech firms and regulatory authorities must collaborate to
establish the scientific background needed to address the aggregation problem to bring promising
new biopharmaceuticals to market for the benefit of patients and society. This thesis attempts to
be one small piece of that effort, by focusing first on a novel approach to reduce protein particles
to meet current regulatory policies and secondly to influence future policies through improved
standardization and process characterization as prescribed in the International Conference on
Harmonization (ICH) Guideline no Q8 (ICH Expert Working Group, 2007).
1.1. Project Drivers and Overview
Amgen, Inc. is currently the largest biotech company (by revenue) and one of the most respected
firms in the industry. Driven by the mission "To Serve Patients," Amgen strives to develop
innovative therapies for serious illnesses. Focusing on therapeutic proteins, Amgen is
continuously challenged by the complexity of developing and manufacturing such products. One
possible challenge in bringing these products to market is protein aggregation and the formation
of aggregates into protein particles, some of which are visible to customers. Not only does
protein aggregation limit the ability to bring novel molecules out of Research and Development,
but it can also present significant challenges to products that have been successfully
commercialized. Protein aggregation is highly complex because the mechanism is incompletely
understood and while the problem is difficult to measure quantitatively it is tightly regulated
under limited information. Current regulation states that products labeled as "clear", rolling off
of the manufacturing line and exhibiting detectable levels of visible protein aggregation must be
scrapped and result in lost material, as rework is not an option. This yield loss can impact two of
Amgen's main goals: serving every patient, every time and delivering value to shareholders.
This work attempts to explore the problem of visible protein particles through two main avenues.
It is divided into work looking to meet current regulatory criteria and that looking to influence
future regulation. In depth attention is given three main elements to address the current
environment: process changes, analytical characterization and organizational improvements. An
experiment was designed to jointly examine both changes to manufacturing processes using
novel filtration applications intended to reduce or remove protein particles from solution and
analytical tools intended to improve characterization. Organizational dynamics and resource
allocation present an extra layer of complexity and are discussed in relation to leveraging
knowledge regarding particles. In influencing the direction of regulation, three objectives are
discussed: the need for improved characterization, industry collaboration and a healthy interface
with regulatory bodies.
1.2. Problem Statement
As the biopharmaceutical industry continues to advance, it is the responsibility of regulatory
bodies to update regulations based on the most recent good science and the responsibility of
manufacturers to meet those regulations. Novel therapeutics, particularly high concentration
proteins, have a propensity to form visible proteinacious particles. These particles meaningfully
differ in nature from foreign visible particles and should therefore be regulated in a context
appropriate to their science starting from early development through the post marketing
experience. Addressing proteinacious particles is a high priority for biopharmaceutical
manufacturers requiring superior organizational management to enable the application of best
practices across platforms and products.
1.3. Thesis Overview
This thesis is designed to add to the body of knowledge regarding the risk mitigation of protein
particles to the biotech industry through two broad categories; meeting new ICH regulatory
standards and influencing future regulation pertaining to the application of new standards to
future drug candidates. In meeting this end, six chapters have been developed:
Chapter 2 provides background information to level set the reader with background relevant to
protein particles and drug product regulation. It includes a basic overview of proteins and a
general understanding of protein aggregation followed by both historical and current regulatory
measurements and acceptability criteria. It also provides context around the extensive impact
protein particles could have on process characterization at a biotech firm and on the patients it
serves.
Chapter 3 explores potential solutions to the problem in a framework created to highlight particle
relevant processes in the commercial development of a biological pharmaceutical. A literature
review of current academic and industry research is provided to arm the reader with a concise
understanding of distributed efforts and to highlight the importance of a holistic approach.
Additionally, it explores the application of organizational changes intended to leverage
knowledge management.
Chapter 4 discusses the importance of comprehensive analytical characterization and briefly
reviews new technologies and method development.
Chapter 5 investigates applications in particle reduction through an experiment using novel
process and analytical technology.
Chapter 6 synthesizes the individual results presented in the thesis into a cohesive
recommendation for a proactive and holistic approach to characterize and mitigate protein
particles.
2. Background
Protein aggregates present a formidable challenge for biopharmaceutical companies and are one
of the many road blocks to fully realizing the potential of protein therapeutics. Chapter two is
intended to provide the reader with background information to understand the complexity of the
problem and the challenge to realize a pragmatic solution. The following sections will deal with
protein particles from a very general base: proteins and their use as therapeutics, a brief
introduction to protein particles, their measurement and regulation, followed by a short
summation of the considerable impact of protein particles on companies producing protein
therapeutic products.
2.1. Protein Chemistry
Proteins, involved in almost all biological activities, are the foundation for therapeutic
biopharmaceutical products. Deoxyribonucleic acid (DNA) both replicates itself and codes for
the production of Ribonucleic acid (RNA) that then codes for the synthesis of proteins.
Constructed from their component parts (amino acids), proteins are the final product in the
central dogma of molecular biology. Figure 1 describes replication of DNA, transcription from
DNA to RNA and translation from RNA to protein.
Replication Transcription Translation
DNA RNA Protein
Figure 1: Molecular Biology Central Dogma
Under the proper conditions, proteins are self-assembling and spontaneously fold into their
native conformations in a matter of seconds as determined by their primary structure or sequence
of amino acids. Proteins are flexible and fluctuating molecules in which molecular dynamics
simulations indicate that native proteins structures each consist of a large number of closely
related and rapidly interconverting conformational substates of nearly equal stabilities (Voet,
2004). The flexibility and sensitivity of these molecules make them both difficult to characterize
and at high risk of degradation and aggregation into a variety of unpredictable conformations.
2.2. Protein Therapeutics
Recombinant DNA techniques and similar applied biology technological breakthroughs have
made it possible to create and manufacture human proteins characterized as biopharmaceutics
and generally referred to as protein therapeutics. Protein therapeutics are capable of treating
diseases when properly used and differ significantly from traditional small-molecule
pharmaceuticals. Small-molecule therapies are typically 20-100 atoms in size, homogenous in
purity and created through organic synthesis. Protein therapeutics (large molecules) are instead
much larger, ranging from 200-50,000 atoms, heterogeneous, produced biologically and have a
number of advantages over small-molecule drugs. Proteins serve a highly specific and complex
set of functions often with less potential to interfere with normal biological processes and
because the body naturally produces many of these proteins, they are often well tolerated and
less likely to illicit an immune response (Leader, 2008). Therapeutic proteins are organized
below by Leader (2008) based on their function and therapeutic action.
Protein therapeutics with enzymatic or regulatory activity
* Replacing a protein that is deficient or abnormal
* Augmenting an existing pathway
* Providing a novel function or activity
Protein therapeutics with special targeting activity
* Interfering with a molecule or organism
* Delivering other compounds or proteins
Protein vaccines
* Protecting against a deleterious foreign agent
* Treating an autoimmune disease
* Treating cancer
Produced biologically in bacterial or mammalian cells, proteins are harvested and purified by
filtration or fractionation using characteristics such as solubility, ionic charge, polarity,
molecular size and binding specificity. The purified protein is then formulated into a stable
solution safe for delivery to the patient. Because proteins are sensitive to digestive enzymes in
the stomach, they must be delivered in an aqueous parenteral form including intramuscular,
subcutaneous or intravenous injection. The final drug product is defined as both the protein in a
formulated solution (lyophilized or aqueous) and the delivery system (vial or pre-filled syringe).
2.3. Generic Protein Therapeutic Manufacturing Process
Biopharmaceutical manufacturing process differs greatly from traditional chemical
pharmaceuticals and is reviewed below in Figure 2 (Adapted from Walsh, 1999).
Fermentation
If protein is expressed intracellularly
Recovery of producer cells
(centrifugation or filtration)
Cellular disruption
(homogenization)
Removal of cellular debris
(centrifugation or filtration)
Initial purification/concentration
(ultrafiltrationlion exchange
or precipitation)
If protein is expressed extracellularly
Removal of cells from media
(centrifugation or filtration)
Concentration of product-containing
Extracellular media
(ultrafiltration or precipitation)
Chromatographic purification
(usually 24 steps)
Adjustment of potency and
Addition of excipients
Sterile filtration and aseptic filling
Freeze drying
Powder preparation
Powder preparationZ/
Sealing of final product container,
Labeling and packaging
Figure 2: Biopharmnaceutical Manufacturing Process Overview
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The Formulation, Fill, Finish processes are especially important for particulate considerations
and are covered in more detail in Figure 3 (Rathore, 2008).
Figure 3: Formulation, Fill, Finish Operations
2.4. Particulate Matter in Therapeutic Parenterals
Particulate matter presents a host of problems in the manufacturing of therapeutic proteins. Sub-
visible and visible Particles range in material type (i.e. foreign or proteinacious), size, color,
shape, buoyancy, and exist in range of three orders of magnitude (1 to 1000 gim). The range from
0.01 to 1 Epm represents semi-soluble aggregates which serve as pre-cursers or nuclei to the
larger particles. Because parenterals are injected into patients, acceptable levels of particles are
regulated by the FDA (to be further explained in Chapter 2.5). Today, the elimination of particles
from injectable solutions is heavily dependent on the use of filters (Barber, 2000). However, it is
thought to be virtually impossible to remove every vestige of unwanted particulate matter from
an injectable solution. Furthermore, it becomes increasingly expensive to remove particulate
matter as the size of the particulate decreases (Barber, 2000).Table 1 illustrates the variety of
contaminants and their sizes reported in parenteral solutions (Groves, 1973).
i
Table 1: Approximate Sizes of Some Contaminants Reported in Intravenous Solutions
Contaminant Size Range (prm)
Insect parts 20-1,000
Glass fragments 1-1000
Rubber fragments 1-500
Trichomes 10-100
Metal particles 1-100
Cellulose fibers 1-100
Lubricating and machine oil 1-100
Plastic fragments 1-100
Starch 5-50
Fungi 5-10
Zinc oxide 1-10
Calcium carbonate 1-10
Plasticizer droplets 1-10
Silicone oil droplets 0.01-10
Carbon black 1-5
Clay 1-5
Diatomaceous earth 1-5
Talc 1-5
Bacterial fragments 0.1-5
Viruses 0.05-0.1
The types, sizes, and numbers of particles in solution are particularly important when
understanding patient safety and efficacy. While some particles may have a serious adverse
effect on the patient (e.g. blocking the pulmonary micro-capillary network or by an immune
response), others may only be considered a cosmetic defect. In such a case, the presence of
particles may affect customer perception of a protein therapeutic and impact its financial
performance in a competitive marketplace. There are two types of particles that find their way
into the therapeutic treatments; foreign particles that are not related to process contact materials
(extrinsic particles) and particles that are related to the process environment (intrinsic or
proteinacious).Table 1 illustrates mostly extrinsic particle types, which are arguably less difficult
to find and characterize. Proteinacious or intrinsic particles are a function of protein aggregation
and are the focus of this work.
2.4.1. Extrinsic Particles
Extrinsic particles are those that enter the product or its container during manufacturing
processes. They typically include rubber, metal, or plastic coming from the manufacturing
environment, such as paint chips or dust (Barber, 2000; E. Freund, personal communication,
2008). Although foreign particles can be introduced at multiple steps in the manufacturing
process, filtration and purification processes are in place to remove such irregularities, making
the final transfer of product to the container most susceptible. Due to the potentially serious
adverse effects extrinsic particles on patient safety, the FDA has developed current Good
Manufacturing Processes (cGMPs) in which the control of particles in pharmaceutical processing
is one element. Key points of cGMP controls that can impact particulate matter control include:
control and/or classification of manufacturing areas, positive pressure environments, airflow
patterns and airflow velocity, filtered air, particle count monitoring, suitable premises, equipment
and materials, trained personnel and adequate transport and storage (Barber, 2000). Although
extremely important to consider, extrinsic particles are not the focus of this work and are only
discussed with respect to intrinsic particles.
2.4.2. Intrinsic Particles
Proteinacious particles, more often called protein aggregates, are a group of particles held
together by strong atomic or molecular forces (Barber, 2000). Aggregation is generally
considered the process by which protein aggregates with a secondary structures at the monomer
scale are created that differ significantly from the dominant (therapeutic) structures in the native
state (Roberts, 2007). Aggregate sizes cover a range from small oligomers to visible "snow
globe" like precipitates. Generally only the smaller species can be reversed (Philo, 2006). While
the kinetics of protein aggregation is generally poorly understood, its affects are critical to
human health, product shelf life and ultimately the success of therapeutic products, (Cleland,
1993; Roberts, 2003) which explains the importance of this challenge.
Aggregation is thought to proceed from a native monomeric soluble protein, through the
formation of aggregation-competent species, followed by association reactions to form non-
native protein-protein contacts, resulting in the formation of higher molecular weight aggregates
(Roberts, 2003; Chi, 2003). Figure 4 depicts a simplistic scheme of the reactions that can occur
during initial aggregation of a protein where protein N is the native protein, N* is the
aggregation competent species, and Ai is an aggregate with subscript i denoting is assembly state
(Chi, 2003).
N +- N*
N* + N* - A2
N* + A 2 -~ A 3
N* + A3 -~ A4
N* + Am-I -- Am
A2 + A2-- A4
A2 + A. -- As
A2 + Am-2 --* Am
Ai + Aj -Ai+j
Figure 4: Aggregate Formation Schematic
Often divided into "soluble" and "insoluble" or "reversible" and "irreversible" categories, there
is unfortunately no uniform terminology for aggregate sizes or types (Philo, 2006). It is not
entirely clear when an aggregate transitions from an "oligomer" to a "particle," however,
aggregates are generally understood to exist along some dynamic range with the potential to
move in and out of certain states depending on factors such as solvent components, excipients,
organic modifiers, pH, temperature and time in addition to processing constraints (Wang, 2004;
Philo, 2006). Variations in these factors amongst therapeutic proteins are only one of the
challenges in studying proteinacious particles. However, characterizing protein aggregation is of
fundamental importance to the manufacturing, storage, and delivery of biopharmaceutical
products.
2.4.2.1. Challenges of Formation Kinetics and the Dynamic Range
Roberts (2007), Figure 5 below, depicts protein folding in its simplest form and the multi stage
process of non-native aggregation as currently understood. Non-native aggregation is generally
considered to be any process which creates protein aggregates with secondary structures at the
monomer scale that are significantly different from the dominant structures in the native state
and for which these structures are at least putatively stability or influence the morphology, size,
toxicity, or material properties of the resulting aggregates (Cox, 2005; Rosenberg, 2006).
Monomers that are incompletely folded or non-native are most often implicated as the reactive
precursors that subsequently assemble to form higher molecular weight aggregates (Chi, 2003;
Dobson, 2004). The portrayal of native polymerization in Figure 5 does not take into account
conformational changes or aggregate-aggregate association, but represents the historical basis for
a number of kinetic models of protein aggregation (Roberts, 2007).
(Addit;ional) Folding
Interrmediates
jartiaaily Unbolded
"Reactive Monomer
e. hbgr?-
•ntym"
iebrilS
(111)
Reversible. Ncnrative
Oligornrers(Prenuclei
Figure 5: Non-native Protein Polymerization
/
In his review, Roberts (2007) also notes that "many if not all of the intermediates depicted in
stages II, III, and potentially stage IV are often difficult if not impossible to reliably quantify or
even detect experimentally..." The inability of most available experimental methods and
analytical tools to detect and quantify key intermediates in non-native aggregation (Philo, 2006)
or even to distinguish their structural features from those of upstream and downstream species in
the mechanism remains a principle challenge (Roberts, 2007). Most methods are used for
relative qualitative analysis and describe the aggregates using a diverse assortment of
information, often not overlapping with other analytical tools or informative for all practical
purposes. Because aggregates exist in a dynamic range, in conditions which are exceptionally
difficult to exactly replicate, it is not surprising that the population distributions of these
aggregates are so difficult to measure.
2.5. Regulation of Protein Therapeutics
As the official public standards-setting authority for healthcare products, including protein
therapeutics, manufactured and sold in the United States, the U.S. Pharmacopeia sets standards
for the quality of these products. After the FDA has approved a pharmaceutical product, the
USP works with manufacturers to develop tests, procedures and acceptance criteria standards
that are legally enforceable by the FDA. International manufacturers who make products for sale
in the U.S. must also comply with USP standards and compendial methods. The purpose of the
USP is to protect the patient by ensuring that drugs administered are of the highest quality with
regard to purity, efficacy and safety (Barber, 2000; U.S. Pharmacopeia, 2008). Furthermore,
determining testing standards and acceptance criteria of particulate matter is one of the many
ways the USP ensures patient safety. Similar international organizations exist for products sold
globally which include the European, British, and Japanese Pharmacopeias which each provide a
listing of a wide range of active substances and excipients used to prepare pharmaceutical
products.
2.5.1. Regulation of Particulates in Parenterals
The solution product cleanliness requirements of the pharmaceutical industry (U.S.
Pharmacopeia [USP] <788>) were historically derived from the human body and the physical
dimensions of its vasculature (Barber, 2000). According to the USP, particulate matter is
defined as mobile, randomly-sourced, extraneous substances, other than gas bubbles, that cannot
be quantified by chemical analysis due to the small amount of material that it represents and to
its heterogeneous composition (USP, 2006). Assuming that the smallest capillary of the human
body has a diameter of 7 pm (the diameter of a red blood cell) the particulate matter of concern
is considered to be that larger than 10 pm (USP) and often more conservatively 5 pm (European
Pharmacopeia) (Barber, 2000). Although there is currently no absolute definition of "visible", as
it is a probabilistic determination (Knapp, 1996), for the purposes of this discussion, subvisible
particles are defined as <150pm based on the upper limits of the light obscuration instrument
used to measure them (to be discussed in more detail under the Analytical Techniques section in
Chapter 4). The tests outlined by regulation to measure particles are performed for the purpose
of enumerating subvisible extraneous particles within a specific size range. Current USP limits
for extraneous particles classify a failed product if it exceeds a determined concentration of
particles in solution. Table 2 outlines the USP guidelines for a concentration of particulates of
varying sizes in solution. The guidelines are followed based on total volume and sampling
(individual or pooled) for particulate testing. According to both techniques (the light obscuration
and microscopic method), when samples are pooled solutions for parenteral infusion or solutions
for injection are supplied in containers with a nominal content of more than 100 mL, the
Particles per mL rule is applied. When solutions for parenteral infusion or solutions for injection
are supplied in containers with a nominal content of less than 100 mL, the Average Particles per
Container rule is applied.
Table 2: USP <788> Particulate Matter Limit Classification
Average Particles Average Particles
per mL per Container
>10 pm >25 pm >10 pm _25 pm
Light Obscuration Method 20 3 6,000 6000
Microscopic Method 12 2 3,000 300
In addition to interfering with arterial passage, protein aggregates pose a risk in terms of
generation of immune responses to the therapeutic protein product. Of principal concern are
those immune responses associated with adverse clinical effects: creation of a neutralizing
antibody that inhibits the efficacy of the product, cross reactive neutralization of an endogenous
protein counterpart, or severe immediate hypersensitivity responses such as anaphylaxis
(Rosenberg, 2006). For example, early commercially available Human Serum Albumin or
pasteurized plasma solutions containing 5-15% aggregates caused severe anaphylactic responses
in some patients (Ring, 1979). The extent to which these responses impact therapy is determined
by multiple factors, but because protein aggregates can in certain cases induce immune
responses, manufacturers should employ several measurement methods for robust assessment of
protein aggregates in products.
2.5.2. Historical Measurement of Particulates in Parenterals
The two basic approaches for determining particle size distribution and concentration in
injectable solutions are the microscopic technique and the automatic particle count devices using
light obscuration. The microscopic technique is typically used to find information on particle
shape and source identification. However, the Light Obscuration technique is considered to be
more reproducible, faster, and robust in determining quantitation (DiGrado, 1970). Each of these
techniques, including their capabilities and limitations, are briefly reviewed below.
2.5.2.1. Light Obscuration
The Light Obscuration (LO) Liquid Particle Counting System relies on light obscuration to
detect and quantify the number of particles and their size range in a given test sample.
Introduced in 1969, the first and current instruments operate on the interaction of an intense
collimated and focused beam of light with a particle suspended in a liquid medium (Barber,
2000). Particles are forced to pass through a narrow view volume between the light and a
photodiode detector. The presence of particles is measured by the variation in light intensity
which is then translated to a voltage signal. As a result, the machine must be calibrated to an
ideal standard particle, such as high contrast polystyrene microspheres of a certain size, which
greatly differ from the properties of a protein particle.
Capable of detecting particles as small as 21pm, optical effects and electrical and mechanical
functions of the system have inherent limitations. Because the technology has made very few
changes over time, Barber's (2000) observations are still highly relevant and are summarized
below as core concerns in relation to pharmaceutical particle counting: "The variation of light
scattering with particle transparency, refractive index, and size has serious implications for the
sizing accuracy of counting when particles of different transparencies, sizes, colors, and surface
textures are present in the sample." He elaborates that the primary mechanical limitations are
optical or physical coincidence: "In this case, multiple particles are simultaneously present in the
view volume or sensing zone of a sensor and are sensed as one particle. This results in the
collection of an artificial count at a size generally corresponding to the cumulative cross-
sectional area of the particles being considered." Despite these limitations, the technology and
methods have been accepted by regulatory bodies and remain established.
Additional limitations of the mechanics and technology
* Refractive index dependency of the
LO measurement
* Validation and count accuracy
* Resolution effects
* Sources of erroneous count data
* Particle size and shape bias
* Air or gas bubbles
may include:
* Excessive degassing
* Variability due to sampling effects
* Issues relating to nonaqueous
vesicles, color and viscosity
* Interferences from subcountable-
sized particles
* Intermittent instrument problems
2.5.2.2. Manual Light Microscopy
The manual microscopy test is intended to provide a qualitative method for identifying particles
that may be present in a solution and for determining their characteristics. This test enumerates
subvisible, essentially solid, particulate matter in pharmaceutical products on a per-volume or
per-container basis, after collection on a microporous membrane filter (Barber, 2000). The
method is complex and requires the use of a compound binocular microscope, two illuminators, a
filtration apparatus and a particle controlled laminar airflow enclosure. The sample is essentially
vacuum filtered through the apparatus and all filtrate is collected on the surface of the membrane
having a minimum diameter of about 21mm and porosity of 1.Opm or finer. The membrane is
illuminated and investigated under the specified microscope. Particles are then counted and
characterized accordingly.
The subjectivity of the test means that the key to the effective application of the light microscope
in particle analysis is the availability of an experienced analyst. It requires only basic training
and although it takes more time than does the application of liquid particle counting by LO, it is
not subject to false counts due to air bubbles or artifacts due to immiscible liquids. However,
disadvantages include low reproducibility between technicians, time consuming ultra cleaning of
equipment, low throughput microscopic counting, rupturing of membranes and wrinkling of
dried membranes (DiGrado, 1970; Barber, 2000).
2.6. Business Impact
Beyond the considerable resources invested in the research and development of potential
therapeutics and the opportunity cost of the specific SKU's (stock keeping units) or drug product
presentations that fail to make it to the market due to particle issues, protein particles have an
additional impact on the bottom line. Commercialized products on the market may experience
protein particle problems that generate complaints, reduce the yield of finished goods, affect the
sales of the therapeutic in a competitive marketplace and pose a costly risk of noncompliance
with a regulatory body. Commercial products afford less flexibility for change and continuous
improvement than others in development as their complete processes are established end to end
and approved by the FDA. The expense of changes made to these processes can often outweigh
the potential improvements and make experimentation within the process nearly impossible. In
the future, the ICH Quality by Design (QbD) principles are expected to offer greater flexibility,
provided that more characterization and a greater mechanistic understanding of particle
formation is achieved.
2.6.1. Yield Loss
One of the final steps in releasing finished product includes both subvisible and visible
inspection (manual or automated depending on the container and product type) for foreign matter
and cosmetic defects. In the case of manual visible inspection, certified inspectors hold the
finished goods, vials or syringes, up to a defined fluorescent light against a black and white
background and look for defined defects. Cosmetic defects could include a chipped vial or a
stopper that is not sealed or crimped correctly. However, particulate defects are especially
challenging because it is not always as simple for inspectors to make a defect classification
decision. Products that should be "particulate free" include freedom from both foreign and
native (protein-like) particles. Any product that does not meet the particle requirements are
scrapped without the potential for rework. An acceptable limit for particulates is determined for
a product on a per container or per lot basis using statistical sampling methodology. A defined
fraction of the whole lot may contain higher than expected visible particle levels as a function of
the inspection sampling, and if the lot surpasses the limit, an investigation will ensue including
forensic particle identification. If atypical particles are present throughout the batch, the whole
lot may fail to be released. If a product is labeled (with FDA approval) as "may contain
particles", meaning that it is a expected phenomena and known to pose no safety risk, inspectors
must then be capable of identifying the particles as proteinacious or foreign (visible extrinsic
particles are not permitted) and within an acceptable limit before the lot can be passed. Finished
products that do not meet the appearance specifications are scrapped. Finished product is
obviously the most valuable and therefore losses have the greatest relative impact on the Cost of
Goods Sold (COGS).
2.6.2. Competitive Marketplace and Perceived Quality
Biotechnology companies will soon face the challenge of generic-like competition in the
marketplace with follow-on biologics. Relatively new to the market, biological products in the
initial pipeline have been protected by strong patents and therefore biotech companies have not
had to face product competition typical of most industries. Follow-on biologics or biosimilars
are the generic version of biological products and refer to a protein therapeutic that is
comparable to, but not the same as, a previously approved therapeutic. Although the patents for
some blockbuster biologics have already expired, the production of biosimilars has been stifled
by the Food and Drug Administration's decision for biosimilar approvals. Amongst the industry,
the argument continues as to whether it is possible to safely copy a complex biological
pharmaceutical, like a conventional drug, without additional clinical trials to prove safety and
efficacy. The magnitude of required clinical trials will impact the cost of production and
therefore the ability of biosimilar products to compete with precursor original product. The
recent approval and production of biosimilar products in Europe has confirmed these concerns.
In April of 2006, the European Commission granted market authority to the generics company
Sandoz to produce a follow-on to Pfizer's recombinant growth hormone (Tucker, 2007). Shortly
thereafter, Sandoz was also approved to produce erythropoietin-a (EPO) in Europe. However, it
may not be as easy as it looks. Dutch scientists have found that aggregates due to formulation
changes of EPO, sold as Eprex in Europe, were responsible for an immunogenic reaction that
triggered severe side effects (Louet, 2003) suggesting that it is possible for biotech companies to
provide superior performance through product differences.
Current competition even exists within in the same indication among differing products using
disparate mechanisms for treatment. The TNF blockers Enbrel (etanercept), Remicade
(infliximab) and Humira (adalimumab) are each used in the treatment of rheumatoid arthritis.
The amount and frequency of dosage combined with efficacy and side effects are often factors
that determine patient use. Because these products are often used interchangeably, they also
compete on perceived quality. If a physician feels less comfortable prescribing a therapeutic that
contains proteinacious particles, although equally efficacious, the particle free drug will maintain
a competitive advantage.
2.6.3. Cost of Noncompliance
A noncompliance occurs when a pharmaceutical product deviates from the cGMP regulations set
forth by the FDA. The regulations include requirements for methods, facilities, and controls
used in manufacturing, processing, and packing of a drug product (FDA Office of
Pharmaceutical Science, 2008). Divergence from these standards creates serious financial risk
linked to patient safety, FDA fines, increased internal resources, patient trust and lost revenue.
Although oversimplified, the path of noncompliance could include the following. A defective
product leaves the manufacturer and is delivered to a physician whom observes a small white
particle in the vial. The physician reports the inferior product to the company which is in turn
required to report to the FDA. The product is returned to the manufacturer and internal resources
are used investigate the reasons for noncompliance both in the laboratory and the manufacturing
facility. The patient and/or physician may no longer trust the product and choose to switch to a
competing product. In the worst case, the patient could be delivered the product and suffer a
severe reaction causing the patient or family to take legal action. The patients' best interests and
the extraordinary risk of regulatory noncompliance drive pharmaceutical companies to meet
regulatory guidelines. For this reason, products that do not comply due to particle related issues
are indisputably scrapped, yield is compromised and for the most part, risk is avoided. However,
because it is possible for a proteinacious particle to form after inspection or to pass inspection, it
is in the firms' best interest to thoroughly determine all factors that could cause protein particles
to form to more completely address both risk to the patient and the financial security of the firm.
3. Potential Approaches to Address Protein Particle Formation
As biopharmaceutical pipelines continue to fill with the promise of therapeutic proteins,
companies will be challenged to develop and manufacture at a higher standard of quality
consistent with the growing body of product knowledge. Advancements in analytical
characterization enable biotech companies to provide more product characterization information
than ever before. Improved characterization, although constructive to the body of knowledge, is
not always seen positively and has made it apparent that protein therapeutic products are more
heterogeneous than previously thought or reported (Carson, 2005). Regulatory bodies are
expected to increase characterization requirements and standards as more information becomes
available. Protein particle formation is an element of heterogeneity that continues to confound
product stability, efficacy, or the risk of immunogenic side effects. Regulations are designed to
deliver safety and efficacy to patients within a given risk/benefit ratio given the seriousness of
the illness. Therefore, aligned incentives and collaboration between the regulatory bodies and
biotech companies should exist to create the most value for patients.
The youth of biotech companies and their novel products present a growing challenge for
regulatory bodies. In the space of protein particle formation, regulators are learning along side
the companies themselves. As such, biotech companies (particularly those with distinguished
experience) have the resources to significantly contribute to the body of knowledge that will
enable the industry to further develop. For this reason, biotech companies can work to increase
the knowledge base needed to influence regulatory bodies and cooperatively maintain extremely
high standards of safety and efficacy as a function of the risk/benefit ratio. This can only occur
with a collaborative relationship between companies and regulatory bodies. Until that day,
companies must use resources both to meet current regulations as stated and to influence the
regulatory bodies to adopt updated regulations more appropriate to improved technology. The
following sections are designed to focus on efforts that can address current regulatory standards
as written (product, process and organizational changes) and those that can potentially influence
the regulatory environment (industry standardization and collaboration).
3.1. Meet Regulatory Requirements
3.1.1. Change Product or Process
From the initial stages of research to the final delivery of the therapeutic protein to patients, there
are many steps that are designed to ensure product quality and homogeneity. The elements that
influence, impact or detect protein particles can be divided into Molecular Design, Formulation,
Manufacturing Process, Material Interaction (including container) and Inspection. Although
oversimplified, these steps are outlined below. Molecular Design includes research and
development leading to the creation of a stable biologically active therapeutic molecule.
Formulation begins once the molecule is created and serves to incorporate the protein into a
stable solution with excipients to be capable of delivering it to the patient while maintaining the
integrity of the protein through expiry. The Manufacturing Process involves the steps necessary
to create, purify and transform the protein into a deliverable product. Material interaction
overlaps heavily with the Manufacturing Process as it includes the materials the product
interfaces with during these processes, but also includes interaction with the material in the
storage container. Inspection is one of the many steps to confirm product quality before release.
The framework below uses each of these core functions to describe product or process changes
capable of addressing regulatory requirements. Related efforts across the industry are reviewed
in each of the defined categories.
3.1.1.1. Molecular Design
Once a therapeutic molecule is discovered, it can be manipulated to generate candidate
molecules superior to those initially created. Site specific modifications in biotechnology
products may introduce new properties, such as improved stability, or new traits, such as drug
binding and transport (Lundblad, 1997). Site specific modifications are complex and range in
abilities to change the many properties of a protein. Modifications may include a single amino
acid change, a whole polypeptide substitution or a combination of both. They can alter the active
site, binding affinity, and even protein-protein interactions. Achieved through both chemical
modification of the protein itself and mutagenesis of the DNA that codes for the protein, the
combination of these techniques may provide an even better strategy than either alone
(Lundblad, 1997). The use of the glycoconjugate Poly(ethylene glycol) (PEG)2 is a popular
example of a modification that has been successful in altering the stability of therapeutic proteins
including reduced antigenicity (Delgado, 1992) and increased bioavailability (Herman, 1995).
Additional protein conjugates and other modifications including covalent cross-linking, have
created therapeutic derivatives with enhanced therapeutic effectiveness (Hashida, 1994) and that
have also been used to stabilize antibodies (Goldberg, 1991).
By applying a similar methodology, changes in highly aggregation-prone regions and stabilizing
interactions could help prevent aggregation and increase long term stability. When studying
pathological conditions associated with protein aggregation, Chiti et al. (2003) found that
changes in aggregation rates can be attributed directly to the intrinsic effects of the amino acid
substitutions on the process of self-assembly and identified mutations in which the aggregation
rate could be perturbed significantly. By predicting aggregation based on physicochemical
properties of polypeptides and modifying targeted amino acids, Fowler et al.(2005) created
variants of the hormone calcitonin that showed significantly reduced aggregation propensity
while maintaining or even increasing potency. Modifications that disrupt hydrophobic patches in
highly aggregation prone regions, while avoiding changes to residues thought to be important in
biological activity, may permit a rational and robust design strategy for additional therapeutic
proteins. Other increased kinetic stabilizing options may include introducing hydrophobic
mutations, disulphide bonds, salt bridges and metal ions at the protein surface to stabilize and
rigidify regions involved in local unfolding (Machius, 2003; Wang, 2004). As one of the earliest
steps in the development of a therapeutic protein, molecular design modifications offer the
opportunity to proactively improve a molecule using better defined metrics for success.
3.1.1.2. Formulation
After a therapeutic protein has been discovered and produced, several challenges confront
pharmaceutical scientists in the formulation of that protein into a stable solution. Formulation
desires to protect against the threats of shock, shear/shaking, light, air interface, temperature and
pH as a function of protein concentration and time. Formulation types are selected to maximize
the pharmaceutical quality of the product depending on the protein stability, clinical needs, and
pharmaceutical acceptability (Smales, 2001). Successful formulation of proteins depends on a
thorough understanding of their physicochemical and biological characteristics, including
chemical and physical stability, immunogenicity and pharmacokinetic properties (Frokjaer,
2005). Although the complexity of formulation science is too exhaustive for the purposes of this
discussion, it can have significant impact on the chemical and physical stability of the protein
and potentially leads to aggregation and ultimately precipitation (Cleland, 1993).
Surfactants lower the interfacial tensions between liquids and are often added to protein solutions
to prevent physical damage during purification, filtration, transportation, freeze-drying, spray
drying, storage and delivery (Kerwin, 2007). For example: Polysorbates are amphipathic,
nonionic surfactants commonly used in the formulation of protein biopharmaceuticals (Nema,
1997). Polysorbates are both biocompatible and excellent stabilizers against surface adsorption,
but still not a silver bullet. They must be used with caution since under some conditions their
degradation can lead to chemical modification of proteins and interactions with some proteins
may lead to changes in conformation structure with unknown consequences (Kerwin, 2007;
Katakam, 1995). The development of additional surfactants may prove successful in creating
more robust formulations, and thereby increasing manufacturing flexibility while preventing the
phenomenon of protein aggregation.
3.1.1.3. Manufacturing Process
The manufacturing process and formulation are tightly linked and highly dependent on protein
stability. Before a protein is formulated, there exists a complex process of cultivating cells and
then extracting and purifying the highly sensitive proteins of interest. Factors such as heat
exposure, shaking, shearing, freezing, drying and even filtering can individually or collectively
damage the protein during manufacturing. pH adjustment and buffer systems as well as protein
concentration (Narhi, 1999) and ionic strength (Wang, 1999) have been found to be crucial
parameters in controlling protein aggregation during thermal treatment. Additionally, a variety
of surfactants have proven successful in protecting proteins by accumulating competitively with
proteins at hydrophobic surfaces/interfaces and/or binding directly to proteins (Wang, 2005,
Webb, 2002). Surfactants and excipients have also been used to protect against protein
aggregation during freezing and drying. Although aqueous solutions are the preferred choice for
both convenience of use and ease of manufacturing, a lyophilized formulation fosters long-term
stability of proteins that are not stable enough to fill the required shelf life in aqueous solutions
(Smales, 2001). Aqueous and lyophilized formulations are an example of manufacturing
decisions determined by protein stability that substantially alters downstream manufacturing
processes, convenience and cost. Although too great to cover in depth for the purposes of this
work, other manufacturing focused areas of interest could include Ultra Filtration/Diafiltration,
nominal filtration, and other interactions causing product stress such as temperature, shaking and
shearing, and freezing.
3.1.1.4. Material Interaction and Delivery Device
Parenteral solutions are not the solitary concern of regulatory bodies; materials and particularly
delivery devices are in contact with both blood and the solution and are therefore essential to
consider when discussing particles. Protein pharmaceuticals come into contact with a variety of
materials during manufacturing; however, the focus of this section is the material interactions of
delivery devices, including, but not limited to syringes, vials and stoppers. The individual
components of a delivery device may incorporate parts made form multiple forms of metal, glass
or polymeric material, which may each contribute some variable level of unique particles
(Barber, 2000). Silicone oil is used in syringes and stoppers to enable smooth delivery of the
solution to the patient by providing lubrication during the delivery step. It has long been
suspected to induce protein aggregation. It is suggested that the oil may have direct effects on
intermolecular interactions responsible for protein self-association through interaction with
protein surfaces or indirectly through effects on the solvent (Jones, 2005). Tungsten is used in
fabrication of the syringe needle placement cavity and presents a similar complication. It has
been found to leach oxides that cause reactions with protein therapeutic products causing them to
aggregate (Rosenberg, 2006). Delivery device research receives less attention, but is necessary
for a holistic approach. A thorough understanding of the formulated protein product with the
device should include all possible device material interactions as well as device handling
variables including long term storage, shock, agitation, pressure, etc.
3.1.1.5. Inspection
Inspection of final product is one of the last steps before drug product is released to the market.
It includes the subvisible inspection by microscopy or light obscuration and visible inspection by
manual or automated means. Inspection is tightly linked with characterization and in great need
of improved technology (subvisible inspection discussed in greater detail in Chapter 2.5 and
Chapter 4). Visible inspection is focused on detecting both cosmetic defects and visible
particles. Manual visible inspectors are trained and certified to inspect particular products and
differentiate between foreign and proteinacious particles. Because inspection methods are
subjective, it is increasingly important for visible particle inspectors to be well trained in both
particle detection and characterization. If a product is determined by the manufacturer to
naturally contain visible proteinacious particles at a level acceptable by the FDA, visible particle
inspectors are challenged to distinguish proteinacious particles more scrupulously and selectively
pass them through inspection as satisfactory product. Because standard protein particle training
sets are difficult to assemble, inspection experience becomes a more essential factor. Approval
of units containing typical levels of visible proteinacious particles, exhaustive training, and
methodical inspection may provide a solution for yield losses in which a particle free solution is
not possible and solutions containing trace levels of these proteinacious particles must be
determined to be safe for patients without impact to efficacy during clinical trials.
3.1.2. Organizational Changes to Leverage Knowledge
The exploration of biology, chemistry and the human body by academic research institutions and
private and public companies continues to create a massive base of valuable knowledge.
Leveraging knowledge creation, strategic collaborations and joint ventures between academia
and firms allow organizations to capture the value being created through managing the body of
knowledge. Biotech companies, often functionally organized, run the risk of creating functional
islands of information. As a developing science-based industry, there is no superior example
with proven performance over time to act as an example similar to that of Toyota in auto
manufacturing (Pisano, 2007). Practices in knowledge sharing, management and integration,
both horizontally and vertically, remains a work in progress for sustainable performance. Pisano
argues that "as the scientific knowledge base of drug R&D broadens, the challenges of
integrating the relevant pieces become even more difficult and important. To perform well, the
sector requires appropriate mechanisms for bringing together and integrating the right mix of
cross-disciplinary talents, skills and capabilities... the sector also requires micro-organizational
mechanisms for creating truly integrated problem solving and avoiding islands of
specialization". In the case of protein particles, it is apparent that the solution will not lie within
a single functional area or scientific expertise. From early Research and Development to the
final shipment of a commercialized product, and many development steps in between, removing
protein particles will require a holistic approach.
3.1.2.1. Proactive versus Reactive Resource Allocation
The extended timeline for pharmaceutical development presents a challenge for related
developmental resource allocation. Assuming that resources invested earlier in the development
lifecycle are proactive in addressing a problem, while those allocated later are reactive, a biotech
firm can create a strategic advantage by optimizing resources by a function of risk and payoff.
Proactive resource allocation in the biotech industry, although possibly more impactful, adds an
extra layer of complexity. The earlier a product lies in the development lifecycle, the more likely
it is to never make it to market. As a molecule passes from preclinical tests to Phase I, II, and III
of the commercial development, the likelihood of the molecule continuing to the market
increases significantly. The early investments must therefore be weighed against the outlying
payoff if the molecule is in fact successful. The balance of risk and cost, Figure 6, may change
depending on the progress, including timely regulatory filings, of the development lifecycle.
Early investments are riskier because the molecule may fail, but eventually lower cost if the
molecule is successful. The opposite also applies.
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Figure 6: Drug Development Risk and Cost Tradeoff
The framework used in this thesis to analyze a potential approaches to address protein particles
was created and presented to correlate to the developmental time frame. Molecular design is one
of the first steps after a target or molecule is identified while inspection is one of the final steps
after the molecule has been manufactured and determines its release to the market. The steps in
between (formulation, material interactions, process development) can exist in parallel, and
although not to scale, also correlate to the development timeframe. Different functional groups
are roughly responsible for each of the defined categories and are also an example of the
potential to create knowledge silos. Each group proposes projects that consume resources while
generating necessary knowledge for regulatory requirements as well as academic interests.
Assuming that the objective is to maximize the value of the firm, projects that have the greatest
impact should also receive the highest priority.
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Figure 7: Project Dashboard
Figure 7 was created to visually communicate the allocation of resources to each of the
framework categories and therefore demonstrate the distribution of proactive versus reactive
resources as well as project prioritization by impact. Resources were calculated using project
proposals and generally rough estimations of requirements. For this model to be valuable, the
impact is both an important and extremely difficult portion to quantify. To complete the exercise
for the purposes of protein particle mitigation, calculation was limited to the value of finished
goods yield improvements. Other valuable calculations could include aspects such as material
usage, labor and infrastructure requirements.
3.1.2.2. Project Mapping and Testing Integration
To capture value from a holistic approach, it is necessary that functional specific information is
effectively shared across all functions tied to a common goal. As each functional group initiates
a project related to particles, it is important for efficient collaborative purposes that the project
members be connected to other researchers that have had or will have some involvement in a
similar project. Without an accurate understanding of both ongoing and completed projects,
results and implications, and the value of follow on studies, inefficient resource allocation is
inevitable. Implementation of cross functional particle project teams is one sample example of a
holistic approach that can address this risk.
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Figure 8: Research Project Map
Figure 8 is an exhibit of a project map created for particle related projects. Because the emphasis
of this work is on proteinaceous particles, the foreign heading is included to show that projects
related to foreign particles could be either linked or overlapped with those proteinaceous.
Similar to the Project Dashboard, the project headings are divided by relevant functional groups
involved in protein particles. Particle related projects and involved researchers are organized
under each core functional group responsible for the project (as determined by resource
allocation) and divided into categories of internal resources and academic partnerships. These
categories are separated because typically, projects through academic partnerships are more
theoretical by nature and vary in output expectations, but may provide less calculable value.
Access to resources and ease of communication also differs between these groups. By mapping
each of the projects, researchers and managers have a resource to understand ongoing work
outside a narrow scope, determine gaps, and collaborate when necessary. It is assumed that the
researchers have a form of communication (meetings, email, etc.) and an information sharing
system in place to record information that together makes knowledge sharing possible.
By managing these projects holistically, it is possible to collectively set expectations and
deliverables, track progress, and measure value upon completion. Additionally, best practices
can be determined and shared across platforms. Necessary resources, either a cross functional
team or project management support, should be determined by the total workload and desired
levels of integration. In the interest of efficiency, it is then possible to determine if follow on
work is necessary, valuable, and who should be involved to provide the most value. Likewise, if
the project does not require follow on work, but should instead be installed as a standard test in
development and manufacturing, resources and outputs are well understood for successful future
inclusion.
3.2. Influencing the Regulatory Environment to Change
The novelty of biotechnology breakthroughs and its applications create a challenge for regulatory
agencies and biopharmaceutical manufacturers alike. Industry and regulatory collaboration
presents an opportunity for pharmaceutical manufacturers to innovate superior manufacturing
and quality processes.
3.2.1. Process Analytical Technology and Quality by Design
Biopharmaceutical products are created through a combination of tightly controlled
manufacturing processes and end-product characterization. Because completely characterized
products are not always possible given available technologies, manufacturing processes also
define the end product (Krull, 2006). The Process Analytical Technology (PAT) Initiative
intends to drive collaboration between the FDA and pharmaceutical manufacturers to understand
and control manufacturing processes. PAT is only briefly covered in this text, but is defined by
the FDA a "a system for designing, analyzing, and controlling manufacturing through timely
measurements (i.e., during processing) of critical quality and performance attributes of raw and
in-process materials and processes with the goal of ensuring final product quality" (FDA Office
of Pharmaceutical Science, 2008). Biopharmaceutical companies are encouraged to better
characterize both products and processes to increase flexibility and trust between manufacturers
and regulatory agencies. It is logical to assume that the increase in analytical tool demand from
both organizations will drive growth and innovation. It is the responsibility of the firm to
strategically use these tools to increase trust, continuously improve processes, and prevent
rejects, scrap, and re-processing. The Quality by Design (QbD) element of PAT stipulates that
key performance parameters are postulated early in the development process. The designed
product and process should be robust for these parameters (Woodcock, 2004). Using these
principles, product quality and performance should be achieved and assured by the design of
effective and efficient manufacturing processes and product specifications based on mechanistic
understanding enabling continuous improvement and "real time" assurance of quality (Berridge,
2004). Because the path to achieve these principles is not entirely known, manufacturers have
the opportunity to be an even greater part of its development.
3.2.2. Industry Collaboration and Standardization
An important aspect of collaboration with regulatory agencies includes collaboration and
standardization within the industry. By sharing non-proprietary knowledge and collaborating on
issues related to regulatory oversight, biotechnology firms have the potential to amplify the value
of the industry. As the path to achieve PAT and QbD is still being determined, each firm has
product and process experience capable of collectively paving the road. Proteinacious particles
are arguably a challenge for any firm producing high concentration protein therapeutics.
Industry collaboration creates a single voice to best determine the process specifications and
product design criteria that will ensure safety to patients and trust in the regulatory partnerships.

4. Case Study in Improving Analytical Characterization
The nature and complexity of biological products has hindered comprehensive characterization,
which differs greatly from small molecule pharmaceutical products. However, increasing
instrument capabilities, computing power and regulatory expectations to better understand
products is causing biotechnology companies to invest in additional technologies. The goal of
this chapter is to compare emerging tools and technologies in development with the current
compendia in both the visible and subvisible ranges. The review will include practical
considerations and anecdotal information from technicians and researchers familiar with the
equipment in addition to equipment manufacturers' claims.
4. 1. Analytical Characterization Tool Review
The aim of this section is to investigate tools and technologies focused on the range from 1 Rlm
to 2 mm. To best understand both the capabilities and limitations relative to the purposes of
therapeutic protein development, structured interviews were conducted with the principle users
of each of the tools. The interviews were designed to identify parameters including precision,
accuracy and artifacts as well as operating parameters such as throughput, sample manipulation
and ease of user interface. Although some of this data was in a quantifiable form, most elements
were subject to the user and the substance (varying products) being analyzed. Although not a
principle user, the author offers anecdotal insight based on operating experience as well.
Hiac/Royco Liquid Particle Counting System
The history, theory, capabilities and limitations of light obscuration were discussed in detail in
Chapter 2.5.1. The Hiac/Royco Liquid Particle Counting System a commonly used tool
(mentioned in USP guidelines) for light obscuration particle analysis in the pharmaceutical
industry and is pictured below in Figure 9 (Hach Ultra, 2008).
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Figure 9: (A) Principle of Light Obscuration. (B) Hiac 9703.
Micro-Flow Imaging
As advances in detection technologies and analytical methods have emerged, BrightWELL
Technologies Inc. has combined microscopy, digital imaging, fluidics and image analysis to
automatically enumerate and characterize (in terms of size, shape and transparency) particulate
matter in liquid samples (Brightwell Technologies, 2008). Micro-Flow Imaging (MFI) uses flow
microscopy technology and operates by capturing images of suspended particles in a flowing
stream with both a high (14X) and low (5X) magnification option. The images for analysis are
selectively captured by the user, as predetermined by a set of criteria, and stored for future
analysis. The chosen number of images to be captured does not impact the particle count. The
sample volume in each frame is defined by the flow cell geometry which enables the MFI to
detect approximately 80% (low magnification) and 50% (high magnification) of the passing
volume. Both high and low magnification cannot be used at the same time. The MFI features
sample introduction gravity-assisted or by aspiration methods and draws volume using a
peristaltic pump.
The flow images are seen in real time on the screen while the software uses an algorithm to
calculate particle size as a function of distorted pixels. The software creates an initial histogram
with a distribution of particles sizes as chosen by the user (< 0.25pm increments in size).
However, the stored images can then be sorted by multiple criteria including aspect ratio,
diameter, size range, etc. for additional characterization. To optimize the view, flowing images
can be seen in both binary and grayscale form. Images can be stored as TIFF or BMP depending
on desired resolution and storage space. The options described above are significant in
providing the user with increase flexibility to more fully characterize a variety of products.
<.-J :.E~a~
Figure 10: BrightWELL DPA 4100
Figure 10 depicts the apparatus where sample is added to the sample syringe with an optional
micro-stirrer (Brightwell Technologies, 2008). The sample then passes through the flow cell
where the camera and optical assembly detect particles and record images.
Advantages
Although not a complete solution, the MFI offers a number of advantages that enable more
complete characterization of protein therapeutics. The chief advantages are outlined below.
* Ability to capture and store images of particles while in concentrated solution
* Low flow rate reduces shear forces and the risk of particle fragmentation
* Option to fill particle images from outline that appear semi-transparent enabling a size to
be determined from the total area
* Software characterization features capable of filtering and sorting data by morphological
parameters and creating histograms, trend charts, and scatter plots.
* Greater maximum particle concentration detection (275,000 particles/mL at 2.5pm)
* Increased sensitivity in comparison to light obscuration
" Larger magnification range in comparison to light obscuration
* Results are less dependent on particle shape or material type
Disadvantages
The MFI technology is new to biotechnology and currently under rapid development. Although
some of the disadvantages are outlined below, it may be possible that they also exist in light
obscuration, but are only now being visualized. The disadvantages include those experienced by
Amgen researchers and may differ from the manufacturer's claims or specifications. Because
the technology is relatively new to Amgen, it is possible that some of the disadvantages could be
reduced or removed through protocol optimization.
Instrument Related
* Precision and accuracy drop for smaller particles under low magnification
* Fluid transitions of differing conditions cause visual streamlining disruption on top and
bottom of flow cell
* Miscibility issues may lead to potential miscounts and generation of air bubbles
* Flow cell and optimized illumination of the flow cell are highly influenced by the type of
solvent used and may require destruction of sample for optimization without analysis
* Flow cell cleaning and optimization as well as miscibility issues can impact protocol and
cleaning procedures which significantly increase testing time
* Particulates or water spots can become permanently embedded in flow cell. Excessive
buildup introduces miscount risk and requires replacement of flow cell
* Large sample requirement (manufactures specifications differ from current protocol
which requires >5mL of sample)
* Image capture and storage requires non-trivial amount of space
* Operations, cleaning and data analysis requires significantly greater periods of time than
does light obscuration
* Risk of sensor drying out (may permanently render flow cell unusable)
* Dirty sample tube (dried residue)
* Particle trap tube clogging (prevents constant flow)
Sample Related
* Air bubbles in samples
* Aggregate creation by erratic motorized stirring
* Residue carryover in syringe or stir rod
* Sampling error
* Subjective interpretation of image results
Manual Microscopy with Particulate Filter Analysis System
While manual microscopy has been historically used for subvisible particle detection, the
Particulate Filter Analysis System (PFAS) by Clemex attempts to improve the test by integrating
a protein specific dye and automation software. The system presents a visualization
improvement to known technology and image software capable of narrowing the measurement to
particles of interest. As a result, the technician can categorize or eliminate an object by any
shape, size, color or texture attribute.
First, a protein sample is filtered through a specific filter paper (varying pore sizes are available)
followed by a 15 minute soluble protein specific dye that binds protein and changes it to a purple
color. The filter is then placed under the microscope and, using multiple magnification options
(dependent on the microscope type), the PFAS can distinguish between protein and non-protein
particles with the help of the protein specific dye. Software options allow for a variety of
analyses and data on a per particle basis. However, at the current stage in development, the
software and analyses are manually intensive and incredibly low throughput. Although the setup
and operating times are relatively low, the analysis cycle time is much greater and prohibitive of
high throughput analysis. Additional research is needed to understand the complete capabilities
of the system.
Advantages
* Differentiation between protein and non-protein particles
* Air bubbles and dissolved gas do not skew data
Disadvantages
* Subjective analysis and interpretation of results
* Filtration pressure may cause some particles to pass through the filter or alter the native
structure found in solution
* Complex software and incomplete automation result in low throughput of analysis
* Filter imperfections
* Results are highly dependent on uniform lighting across the filter
4.2. Impact of Method Variability
An often overlooked element of analytical tools, particularly those designed for multiple
functions, is the impact of variability of both the sample type, sample preparation and the
operating parameters. Although the key capabilities and limitations have been discussed, the
operating parameters that make such results possible have been neglected. The capabilities listed
above are a combination of both user experience and manufacturing claims. When a user
experience differed from a manufacturer's claim, it was determined to be the actual capability
based on the method and product type. From a product perspective, the precision and accuracy
may vary greatly depending on the type of solution that is being measured and its properties. For
the user, software configurations of both the MFI and LO tools allows the user to manipulate
settings that include the number of runs and run volume and even run speed. Depending on the
limits of the tool, modifications to these settings without a clear understanding of their
experimental implications (such as the limit of detection or limit of quantitation) could have a
significant impact on the validity of the results. Cleaning, calibration, and tool preparation
present similar challenges.
More alarming than the variability in methods, is the inconsistency in scientific reason or method
rationale that could generate variability across labs or end-users. The number of light
obscuration methods and their underlying principles is a noteworthy example. Two different
analytical labs (geographically separated) found two different methods for degassing the samples
prior to testing. One lab used a vacuum chamber to remove all air bubbles and dissolved gas
from the samples. The other lab found that a sample at ambient temperature for two hours with a
rotating magnetic stir bar was able to complete the same task. It could be argued that if the same
outcome is achieved, the variability in the protocol doesn't matter. However, when the
developers in the first lab were asked why they chose not to use a stir bar, they responded that a
stir bar presented another mode to introduce particles and could also generate protein aggregates
through stress prior to measurement. Similarly, when the second lab was asked why they chose
not to use a vacuum, they responded by explaining that a vacuum chamber was too difficult to
implement into standard manufacturing processes. The underlying reasons for diversity of
methods are conflicting and therefore it is natural to question the legitimacy of the results when
comparing different protocols. Because the outputs of the analytical tools are highly dependent
on the input, it is critically important that all samples are treated similarly so that data is
comparable over time, geography and department. Similar inconsistencies existed between two
functional groups (geographically co-located) responsible for creating methods for different
purposes. If developmental functional groups are not operating using standard protocols, it is
possible that the product development could be delayed due to inconsistent or inconclusive
results.
4.3. Summary
Table 3 highlights the technical variation of the analytical tools discussed above and the
difficulty in comparing each of them. Although Field Flow Fractionation (FFF) falls outside the
focused size range of 2pm-200pm, details are included for comparability. They each operate on
a diverse set of scientific principles and vary in manufacturer, software and even objective.
However, the ability to create orthogonal pathways presents an even deeper understanding of
protein aggregates and the development of proteinacious particles in protein therapeutics. For
example: experiments designed to compare data between MFI, Microscopy and visible
inspection could add strength to each of the tests used individually through cross validation. As
emerging technologies continue to become available, it will be increasingly important to
determine the potential value of a single tool as it fits with the current portfolio of analytical
capabilities. Cross validation combined with gap filling could provide a richer understanding
and a higher confidence in the quality of data.
Light Micro-Flow Manual Field Flow
Obscuration Imaging Microscopy Fractionation
Manufacturer Hiac/Royco Liquid BrightWELL Clemex Wyatt
Particle Counting
System
Tool Liquid Particle DPA 4100 Particulate Filter Eclipse 2 Separation
Counting System Analysis System System
Fluid Speed 10 mL/min 0.2 mL/min N/A ImL/min
Manufacturer Range (um) 1.3-400 2.25-400 3-? 0.008-1
Dynamic Range (pm) 2-400 5-400 10-1000 0.002-2
particle images, particle images, relative particle
Information Provided particle concentration particle concentration particle concentration concentraiton
Precision (+/- %) <5 not available subjective not available
Accuracy (+/- %) 5 <10 subjective not available
Sample Size (mL) 5 5 5 0.02
Sample Tested (%) 100 80 100 100
Sample Prep vacuum degas N/A stain dilution
Sample Prep Time
(min/sample) 120 0 20 10
Run Time (min/sample) 5 15 20 45
Analysis Time 5 20-180 120 39751
Tool Prep Time 10 30-60 20 15-30
Calibration latex beads N/A filter background BSA
Table 3: Analytical Tool Comparison
5. Focused Investigation of Particle Reduction through Manufacturing
Process Changes
The sensitivity of protein molecules and complexity of their production create a dynamic
problem for biotech manufacturers. Chapter 3 outlined the areas that should be focused on to
remove or reduce particles in human protein therapeutics. Chapter 5 investigates a potential
change to the Manufacturing Process by adding an additional step to final purification. This
section explores in depth an experiment designed to determine if a process change to bulk drug
substance could significantly remove or reduce particles in formulated drug product immediately
after the new step and remain effective over time.
5.1. Filtration Hypothesis
The deficiency of analytical tools joined with the complexity of protein therapeutics has
inhibited the ability to understand the mechanics and kinetics of protein particle formation. Until
recently, the size range slightly above a typical IgG antibody protein dimer (approximately 5-20
nm) ranging to 2pm was especially poorly understood. Without the ability to visibly monitor
particle formation, it is unclear how a particle forms and at what point the formation is
irreversible. Although future improvements in analytical tools will continue to enhance the
clarity of this phenomenon, the limited current state of knowledge and uncertainty in regulation
might suggest that one way to reduce the risk of particles is to reduce the presence of particles or
remove them altogether.
Filtration remains one of the most utilized techniques to remove insoluble contaminants and
purify drug substance. In a typical manufacturing process, product passes through at least five
filtration steps in addition to multiple chromatography steps to purify the protein. However, the
current filters are not used to remove protein aggregates directly. For example, a viral filter
(similar to those used in the experiment) with a nominal pore size of 20 or 50 nm is used to
remove potential viruses, but because an additional Ultrafiltraton/Diafiltration (UF/DF) and Bulk
Drug Substance (BDS) freeze/thaw step are downstream, the product can experience additional
stresses that could then cause it to form particles (or nucleating agents) after the existing viral
filtration. For this reason, it was proposed that a filtration step be completed after BDS Freeze
and before Formulation, Fill, Finish steps while maintaining the current upstream viral reduction
filtration step.
Protein X is a monoclonal antibody in which data has shown an absence of visible particles upon
inspection immediately after manufacturing and filling but presence of visible particulate
proteinaceous matter over time. Protein particle formation kinetics suggests that a change in
chemical or conformational structure of a single molecule can change its ability to bind to other
proteins (described in Chapter 2) is also known as self-association. It was hypothesized that
small aggregates (ranging from dimer to small oligomers) act as nucleating agents that, with an
altered chemical or physical structure, bind protein product to form larger visible particles over
time. Thereby, removal of these small nucleating agents by filtration will reduce the number of
particles formed over time. Because aggregates can be created at various points in the
manufacturing process, Protein X BDS presents a desirable point to increase manufacturing
flexibility. Before entering the final Formulation and Fill, Finish Process, Protein X BDS is
filtered through a 0.2 pm nominal pore filter composed of Polyvinylidene Fluoride (PVDF). It is
theorized that filters with a smaller pore size will be better at removing the hypothesized
nucleating agents. As a result, adding an additional filtration step in the manufacturing process
that more completely purifies BDS could prevent or delay particle formation in Bulk Drug
Product. The assumptions of aggregation, manufacturing stresses and material interaction
suggest that it is still possible for nucleating agents to form in the processes beyond the proposed
additional filtration step. However, the point of filtration is chosen for ease of implementation
and the probability to reduce or remove the majority of nucleating agents as downstream
processes are considered to be less stressful.
5.2. Experimental Design
To determine the growth of particles over time, the experiment was designed to compare
standard manufacturing control material to material passed through additional filters of similar
composition with decreasing nominal poor sizes at similar conditions. The presence and
formation of subvisible particles was then measured immediately upon filtration and again at
three time points (approximately 30, 60, and 160 days after filtration). Visible particles were
inspected more frequently. The compendial tools (HIAC and SEC) were used to measure
particles and compared to the results of emerging tools (FFF and MFI) of comparable dynamic
range capabilities. Replicates of each filter type were created to identify variability in the
efficacy of the filters to consistently remove nucleating agents.
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Figure 11: Schematic of Experimental Design
Figure 11 is a visual representation of the design of experiment (DOE). To simulate a proposed
change to manufacturing process, we used BDS thawed between 1-14 days prior to filtration.
The BDS was passed through a filter of nominal pore size and membrane composition/chemistry
as that used in the standard manufacturing process. The material passing only through the
manufacturing standard after thaw was used as the control. A 0.22pm filter was used in series to
understand the effect of multiple filtration events at the same poor size. The in-series material
was collected after the first filtration and then passed again through a new filter of the same lot
number. In order of decreasing pore size, material was separately passed once through a
0.10pm, 0.05pm and 0.02pm filter. Only two replicates were created for the 0.05pm and 0.02pm
due to limitations of laboratory equipment while triplicates were created for all other filtration
types. Figure 12, below, illustrates the filtration process in more detail.
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Figure 12: Filtration Experimental Procedure
To ensure that all physical material interaction was free of bacterial contaminants, all glassware,
filtering and handling equipment was sterilized prior to filtration. However, the filtering
equipment was set up on a bench (not hood) and therefore not entirely free of air contaminants.
Because extended material interaction was a consideration, the filtrate was limited to polystyrene
and glass for storage. To create similar conditions for each filter type, each day of filtration
consisted of a manufacturing standard run followed by the experimental filter completed in the
same day. The material was then stored overnight at 4°C in glass containers. The following day,
the filtrate material was transferred in a Pilot Plant Fill Finish hood into two 3cc vials per
replicate (sealed for non-destructive visual testing) and three 50cc vials per replicate for storage.
Filtrate material to be used for immediate tests was placed into 5cc or 10cc vials. To minimize
air contamination, all transfers from storage containers into 5cc or 10cc vials for subsequent tests
were completed in the in Pilot Plant Fill Finish hood. All glassware was depyrogenated prior to
use.
Visual inspection vials were filled in the Pilot Plant Fill Finish hood and sealed for the duration
of the study. The 'visual' vials were stored at 40C, except during the times of inspection as
defined by the standard visual inspection protocol. 3cc vials were chosen for the purposes of
highest accuracy and common inspection form for the certified inspector. The visible particle
inspector (regarded as one of the most capable and well trained) was held constant throughout
the study. Because visual inspection is not destructive, samples were inspected repeatedly over
multiple time points. For the first 30 days, the samples were inspected between every 3-6 days.
5.2.1. Filtration Methods and Materials
The following materials were used for filtration:
* Protein X
" Protein X 'PASS' Buffer (sterile, filtered at 0.22pm)
* Millipore pressure vessel (600mL max working volume, polycarbonate and 5L max
working volume, steel)
* Pressurized gas source (compressed air)
" Pressure regulator (provided desired pressure)
* Pressure gauges (confirmed operating pressure)
* Balances (0.01g accuracy) assume 1g/L density for filtrate to measure volume
* Polystyrene containers (overnight storage)
Step Description Buffer/Solution Duration
Flush the filter with water and remove any air in the lines
1 or filter Water -100L/m2
Once steady flow is achieved, measure normalized
2 water permeability (NWP) Water N/A
3 Equilibrate filter with buffering solution PASS Buffer 2500mL
Warm load material to room temperature from 49-
4 (storage) N/A N/A
Filter load material collecting volume measurements As long as
5 with time at a constant pressure (50mg/mL) necessary
6 Flush membrane to recover product Not performed N/A
Table 4: Filtration Experimental Procedure
Operating
Sample Filter Area Pore Size Pressure Date of
Number Pre-filter Filter Name Lot Number Filter Chemistry (cm2) (pm) (psi) Filtration
1 N/A Millipore OptiScale C5MN15604 PVDF 17.7 0.20 10 9/5/2007
2 N/A Millipore OptiScale C5MN15604 PVDF 17.7 0.20 10 9/5/2007
3 N/A Millipore OptiScale C5MN15604 PVDF 17.7 0.20 10 9/5/2007
4 0.2 Millex GV R3AN92456 PVDF 3.9 0.22 15 9/5/2007
5 0.2 Millex GV R3AN92456 PVDF 3.9 0.22 15 9/5/2007
6 0.2 Millex GV R3AN92456 PVDF 3.9 0.22 15 9/5/2007
7 0.2 Millex VV R1CN73650 PVDF 3.9 0.10 15 9/10/2007
8 0.2 Millex VV R1CN73650 PVDF 3.9 0.10 15 9/10/2007
9 0.2 Millex VV R1CN73650 PVDF 3.9 0.10 15 9/10/2007
10 0.2 Millipore NFR Sample PES 13.8 0.05 20 9/10/2007
11 0.2 Millipore NFR Sample PES 13.8 0.05 20 9/10/2007
13 0.2 Sartorius Virosart CPV 7000483 PES 180 0.02 50 9/13/2007
14 0.2 Sartorius Virosart CPV 7000483 PES 180 0.02 50 9/13/2007
Table 5: Filtration Experimental Conditions
5.2.2. Practical Implications of Filtration Experiment
Despite efforts to create similar testing conditions for different filter types, it was not possible to
maintain consistency along all parameters. As seen in Table 5, the filter chemistry, filter area
and pressure varied along multiple filter types. These variations were each due to limitations
(either by availability of the filter or physical capability of the experiment) that have subsequent
implications. The filter chemistry of the Millipore and Sartorius filters were only available in
Polyethersulfone (PES) where PVDF is more typically used in manufacturing processes. For this
reason, a PVDF filter was used when available and the PES filters were used as necessary.
Different interactions between the protein and surface materials based on chemical and physical
parameters (adsorption, electrokinetics, membrane matrix) may introduce discrepancies in the
way protein aggregates or other particulates are filtered. However, follow-on experiments would
need to be completed to determine the variation and significance of differing filter membrane
composition/chemistry.
The filter area represents the amount of space available for the material to pass through. All
material was passed through a filter with an area of 17.7cm 2 at 10 psi to create a low stress
environment that returned the material to a state as close to manufacturing standard as possible.
A portion of the initial filtrate was saved as the control and the remainder was used for the
experimental filtrations. Scale-down 3.9cm 2 filters were available and usable in 0.20pm and
0.10pm filters. The scale-down 3.9cm2 0.05pm filters were available, but incapable of passing
the required volume upon preliminary experiments due to low flux rates (ml/cm2). The Sartorius
180cm 2 filter differed in shape and dimension and achieved increased surface area through a
chamber filter design. As the surface area of the filter decreased, the same amount of material
experienced more stress to completely pass through the filter. Similarly, as the pore size of the
filter decreased, the material also experienced increased time to pass. This "pore plugging
effect," as a result, required an increase in pressure (house gas) to induce the material to pass
through the filter membranes. Unfortunately, the increased surface area was not sufficient to
compensate for the change in pore sizes and although the surface of the 0.05pm filter was two
orders of magnitude higher, the pressure required a 5x increase from the control but remained
below the max pressure as recommended by the manufacturer for each of the filter housings.
Although the 0.02pm filters employed a >10x increase in surface area, on average, 1/3 of the
protein material was not recovered in the filtrate as measured by reduction in protein
concentration after filtration (see Table 6). These results suggest that at least some protein at
high concentration filtered through the 0.02 pm filter is maintained at the surface of the
membrane due to partial plugging. This hypothesis is further supported by the decreasing flux
over time of filtration.
Filter pore size (pm) 0.20 0.22 0.10 0.05 0.02
Average protein lost to
filter membrane 0% 1% -2% 1% 34%
Table 6: Protein Material Lost in the Filtrate
The time to complete filtration is a similarly significant consideration. The 0.02pm filter
consumed the most time and ranged from four to six hours to pass approximately 90mL of 50
mg/mL BDS. Although this number is expected to vary depending on the flux, which is a
function of the rheology, formulation (excipients), and the product and protein properties, it still
presents a significant technical challenge when considering practical implementation of the
additional filtration step. Again, the filter area would need to increase in size enough to make
the processing time feasible, while minimizing hold-up or dead volumes. Because it is possible
that increasing the surface area would not impact the filtration time, additional experiments to
determine the effective filtration area and pressure would need to be completed. It should also
be recognized that commercial filtration uses tangential flow which minimizes pore plugging.
Due to mechanical complexity of the scale-down model, this feature was absent in the
experiment.
Lastly, it is prudent to consider the stress of additional filtration on the integrity of the protein
itself. As the nominal pore size decreased, the pressure and time required to pass material
through the filter also increased. Foaming of the filtrate was observed during the 0.02pm
filtration suggesting a factor contributing to additional and possible irreversible degradation of
the protein. Further experimentation would be required to determine an optimal filter area and
pressure that might eliminate this problem.
5.2.3. Particle Detection Methods and Materials
The methods and materials are described for each of the analytical tests described in Figure 13
below. SEC, LO and Visual Inspection serve as current compendial tests used for soluble (SEC)
and insoluble particle detection. FFF provides information in a comparable size range to SEC
while MFI is comparable to LO. These tools are currently in development and may serve as
future orthogonal tests to provide richer characterization information. SEC and FFF both
provide qualitative information strictly in the subvisible region. LO and MFI provide
quantitative information in both the subvisible and visible regions while visible tests are
performed by manually by human inspectors and provide information exclusively in the visible
region.
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Figure 13: Particle Detection and Characterization Tests Performed
Size Exclusion Chromatography High Performance Liquid Chromatography (SEC HPLC)
The following materials were used to complete SEC HPLC tests at each of the three time points.
One operator completed all three time points.
* Protein X
* Protein X 'PASS' Buffer (sterile, filtered at 0.22pm)
* YMC Diol-300 8 x 300mm, 5p, cat. # DL30S05-3008WT
* Mobile Phase: 100mM Sodium Phosphate, 600mM NaCl pH 7.0
* Agilent 1100 HPLC, Diode Array detector
Conditions
* Room Temperature
* 1 mL/min flow rate
* 20 minutes
* Wavelength = 215 nm
* 10 pL injection volume of 2 mg/mL (20 p g)
Field Flow Fractionation (FFF)
The following materials were used to complete FFF tests at each of the three time points. One
operator completed all three time points.
* Protein X
(n
* Protein X 'PASS' Buffer (sterile, filtered at 0.22ptm)
* Wyatt Eclipse 2 Separation System coupled with an Agilent 1100 HPLC system
* Wyatt DAWN Heleos MALS detector and an Agilent UV detector set to wavelengths
215 and 280 nm
* Dulbecco's phosphate buffered saline used as the mobile phase (cat# 14190)
* Short channel, 490M spacer
* Large channel, 490N spacer
Conditions
* Room Temperature
* Channel flow of lmL/min
* Crossflow decreasing gradient from 1 to zero mL/min over 30mins
* Dilutions in Protein X PASS Buffer
Table 7 below describes how test conditions changed across the three time points measured.
Variation in the conditions is not expected to have an impact on the accuracy of the data
provided.
Time Point Materials Concentration (m/mL) Total Load (p)
1 Short channel with a 490M spacer 5mg/mL 10
2 Short channel with a 490M spacer 1mg/mL 10
3 Large channel with a 490N spacer lmg/mL 20
Table 7: Field Flow Fractionation Test Condition Variations
Light Obscuration
The following materials were used to complete LO tests at each of the four time points. Three
operators were used to complete all four time points.
* Protein X
* Protein X 'PASS' buffer
* Particle count control standards - shall contain NIST traceable microspheres which have
a certified mean diameter of 15.0pam ±- 0.lapm and a concentration above 1000 (#/mL)
* 10cc Glass vials
* Milli-Q filtered (through a < 0.22Cpm filter) deionized water, 18.2m2
* Liquid particle counting system (Hiac/Royco 9703)
* Liquid borne particle sensor (Hiac/Royco HRLD-150)
* 1 mL sampling syringe
* Small sensor probe
* PharmSpec software
* System configuration
o 10 mL/min flow rate
o Channel setting (pm): 2, 5, 10, 15, 20, 25, and 50
o 0 mL tare volume
o 1 mL sample volume
o 4 runs per test
o Discard the 1st run, average the next 3 runs and report (cumulative counts/mL, or
particles/mL)
" Vacuum regulator
* Vacuum chamber
* Vacuum pump
Step Description Solution Amount/Duration
1 Vacuum degass samples at 75 Torr N/A 2 hours
Until 2pm average cumulative
2 Rinse Milli-Q deionized water particle count 51 particle/mL
3 Run standard Particle count control standards Single run
Until 2pm average cumulative
4 Rinse Milli-Q deionized water particle count 51 particle/mL
5 Gently hand-swirl vial (15-20 times) N/A 10 sec
6 Let sample vial stand N/A 1 min
7 Run sample per protocol N/A 4mL
Until 2pm average cumulative
8 Repeat rinse between samples Milli-Q deionized water particle count 51 particle/mL
9 Repeat sample run until complete N/A Single run
Until 2pm average cumulative
10 Rinse Milli-Q deionized water particle count 51 particle/mL
11 Store probe 70% IPA N/A
Table 8: Light Obscuration Test Procedure
Micro-Flow Imaging
The following materials were used to complete LO tests at each of the four time points. Two
operators were used to complete all four time points.
* Protein X formulated in 'PASS' buffer
* Particle count control standards - shall contain microspheres which have a certified mean
diameter of 15.0pm ± 0.1pm and a concentration above 1000 (#/mL)
* DPA4100 Particle Analysis System (BrightWELL #BP-4100-SYS) equipped with
DPA4100 Software Release 6.9 and an automated peristaltic pump
* 400pm Flow Cell, 1.6 mm wide
* 10 mL Silanized Syringe
* Stopcocks
* Detergent (50% diluted)
* Isopropyl Alcohol
* 10cc Glass vials
* Milli-Q filtered (through a < 0.22pm filter) deionized water, 18.2mQ
* Pipettes and appropriate tips
Step Description Solution Amount/uraton
1 Degas at Ambient Temperature N/A 2 hours
2 Flush Flow Cell Detergent 5mL
3 Flush Flow Cell Milli-Q deionized water 20-25mL
Until 2pm average cumulative
4 Run blank from clean syringe Milli-Q deionized water particle count <10 particle/mL
5 Run standard Particle count control standards Single Run
6 Rinse and optimize filtered protein stock 5mL
7 Run sample per protocol N/A 5mL, 1mL tested
Repeat rinse and optimization between
8 samples filtered protein stock 5mL
9 Repeat sample run until complete N/A 5mL, 1 mL tested
10 Flush Flow Cell Detergent 5mL
11 Flush Flow Cell Milli-Q deionized water 20-25mL
Table 9: Micro-Flow Imaging Test Procedure
Visible Inspection
Replicates of each sample (26 total vials) were created one day after filtration. 1.7mL of
material was transferred to 3cc vials in the pilot plant formulation and fill hood and then
protected from light and stored at 4oC. Due to the subjective nature of the visual inspection test,
a single certified inspector was used to control for variability. The following materials and
methods were used for visual inspection.
* Protein X
* Inspection Station (Custom-built with light source including a 200 foot-candle
fluorescent light with a black and white background)
* 3cc vials and rubber stoppers
Visible particulates were characterized as foreign or protein-like particulates based on the
following general characteristics:
Protein Particle
* Small in size (approximately 0.1-0.4 mm) (Typically but not always)
* Transient (may appear and disappear)
* Color: white translucent and/or "C" shaped jelly-like structure
* Fibrous or amorphous in nature
* Neutrally buoyant in solution
Foreign Particle
* Often larger than 0.1mm
* Color: typically observed are white, yellow, red, blue, black, and brown
* Hard or elastomeric
* Metallic or fibrous
* More difficult to re-suspend
* When swirled usually settle down to the bottom of the vial or syringe (when denser than
formulating) or float up (when less dense than formulation)
Step Procedure
The vial samples were taken out of the refigerator and allowed to equilibrate to room temperature for
approximately one hour. Each vial was then cleaned from the outside using Kimwipes wet with IPA
1 solution to remove any residue or condensate on the outside.
Each vial was slowly inverted and slightly rotated to distinguish between the minor defects on the outside
2 of the vial and the moving particulates
Each vial was held at the top part of the inspection station (approximately 6-8 cm below the light) for
3 optimal viewing
4 The approximate distance from the inspector's eyes to the vial was approximately 7 to 10 in.
5 The approximate exposure time for the actual inspeciton of each vial was about 1 min.
Each vial was inspected utilizing both the black and white background of the inspection station (following
6 steps 1-5)
7 The total number of particulates were counted and documented
8 Once complete, the syringes were covered and placed back into the refrigerator at 4uC
Table 10: Manual Particle Visible Inspection Characterization Method
5.2.4. Particle Detection Results
Particle detection test were completed for 3 time points using SEC HPLC and FFF and for 4 time
points for LO and MFI. As a non-destructive test, visible inspection was completed every 3-5
days for the first month to closely monitor kinetic growth.
5.2.4.1. Subvisible
The subvisible range is defined as particles with a length or diameter below 125pm extending to
the protein monomer. Both the SEC and FFF capabilities are limited to the subvisible region
while the LO and MFI tools are capable of detecting both subvisible and visible particles. LO
and MFI data are reported as cumulative particle counts >5pm. Although the capabilities of the
tools range into the visible region, results are presented in the subvisible section for simplicity.
SEC and FFF both report relative amounts of particles or particulate species as a percent of the
total product analyzed while LO and MFI report data in particles/mL. The results from the
subvisible tests are provided below.
Size Exclusion Chromatography
SEC tests were submitted to an SEC technical lead and completed for three time points ranging
between 1-9 days (Time 1), 35-43 days (Time 2), and 146-154 days (Time 3) after filtration. The
data was analyzed by measuring the relative area of the monomer peak in comparison to
aggregate peaks and low molecular weight (LMW) species. The main peak represents the
amount of monomer while the aggregate peak represents those species larger than monomer
(ranging from dimer to small oligomer) and the LMW peaks represent the presence of
proteinacious material smaller than the monomer.
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Figure 14: Aggregate Detection by SEC
Figure 14 exhibits the amount of total aggregate detected in samples from each filtration type
over time. The trend across filtration types remains consistent, while it is clear that the 0.02pm
filter has the lowest percent of total aggregate. All other filtration types (0.05 pm, 0.10pm and
0.20pm in series) appear to have relatively little impact when compared to the control.
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Figure 15: Low Molecular Weight Protein Detection by SEC
Figure 15 shows the amount of LMW species measured over time. Here the trend is less clear
than in the case of total aggregates. At Time 1, there is a much higher presence of LMW species
in the 0.02Cpm filter and a lower presence in the control.
Field Flow Fractionation
FFF tests were submitted to an FFF technical lead and completed for three time points ranging
between 5-13 days (Time 1), 77-85 days (Time 2), and 161-169 days (Time 3) after filtration.
Similar to SEC, the data was analyzed by measuring the relative area of the aggregate peak in
comparison to the monomer peaks. At Time 1, only one representative sample was chosen from
each filtration category (samples 1, 5, 8, 11, and 14). Here, the amounts of monomer and
particulates are not directly quantified.
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Figure 16: Particle Detection by FFF at Time 1
Figure 16 is a magnified picture analyzing the presence of monomer and aggregate species. For
each filtration type, the large peak at 150 min represents monomer while a similarly shaped, but
smaller peak after monomer would indicate the presence of aggregates. The spike at
approximately 25 min is not an aggregate peak and is instead considered an artifact of the run.
The separation of lines as time progresses is considered a drift artifact and is also not significant.
The above figure does not point toward the presence of any detectable subvisible particulate
thie (lm*1)
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Figure 17: Particle Detection by FFF at Time 2 (A) and Time 3 (B)
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At Time 2 and Time 3, representative samples were not used and instead, each replicate per
filtration type was run once. Figure 17 shows full scale results from the FFF tests at Time 2 and
Time 3. Similar to Figure 16, the large peak is indicative of monomer while a peak thereafter
would be the evidence of subvisible particles. A measurable number of particles was not detected
by the FFF analytical tool in the range of monomer to 2pm during any of the analyses.
Light Obscuration
LO tests were completed by two operators in the course of four time intervals. Measurements at
times 1, 2 and 3 were completed one day after filtration. Measurement at time 4 ranged in 151-
159 days after filtration. During a typical LO by Hiac/Royco test, the 1st run is discarded and the
2 nd, 3rd, and 4th runs are averaged by the instrument software and recorded as average cumulative
counts. However, because an order of magnitude drop in cumulative counts was consistently
seen on the Protein X samples (common only to this protein) between the 2 nd and 3rd run, only
the 3 rd and 4th run were used to create the average cumulative counts used in the analysis.
Because the 2pm range is near the lower bound of the tool and well below both the USP and
European Pharmacopeia reporting requirements (l10pm and >25pm) the results were not used.
Instead, average cumulative counts were calculated using particles >5pm in size. Acceptable
limits for the blank and control were met during each run.
Figure 18: Particle Detection by Light Obscuration
Figure 18 describes the average number of cumulative particles >55pm across filtration types.
Time 1 shows a trend in removal of particles correlating to the filtration type. As the filter pore
size decreases, the average number of particles decreases as well. However, at Time 2 and 3 it is
observed that all filtration types show a relatively similar low number of particles and suggest no
significant removal by any single type. All counts are lower than what is observed at Time 1.
The trend of Time 4 shows an increase in particles from Time 2 and Time 3 across all filtration
types. The 0.02pm in series and Control types also amplify by an order of magnitude. The
particle counts of the 0.05pm and 0. 10pm filter types remain consistently low at each time point
and may illustrate some optimal range of pore size capable of removing particles while limiting
the amount of stress on the protein.
A one-way analysis of variance of cumulative particles by filtration type was completed at each
time point. The results are summarized in the table below.
HIAC Particle reduction over time by filtration type
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P value 0.1647 0.6641 0.4065 0.1075
Table 11: Analysis of Variance Using LO
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0.02pm 0.05pm 0.10pm 0.20pm x2 Control
Filtration Type
Each of the P values is considered insignificant and could easily be this large by happenstance.
More data might help to determine significance. Additional statistical analyses were completed
to understand the significance of the data and are included in the appendix.
Micro Flow Imaging
MFI tests were completed by two operators for four time intervals ranging in 12-20 days (Time
1), 35-37 days (Time 2), 74-76 days (Time 3) and 152-160 days (Time 4) after filtration.
According to the protocol, sample material was used to purge the system followed by a single
run measuring lmL of material. For the same reasons as outlined in the light obscuration results,
the data was analyzed by calculating the cumulative particle counts >5pm averaged across
filtration types of the same pore size. Acceptable limits for the blank and control were met
during each run.
Figure 19: Particle Detection by MFI
Figure 19 describes the average number of cumulative particles >5pm across filtration types as
detected by Micro Flow Imaging. Although the trends are not as clear as those demonstrated by
LO, a similar pattern is detected at Time 4. The 0.02pm filter type makes a significant leap from
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the levels detected at Time 3 while all filtration types are >25% lower than the 0.02pm filter
type. At Time 4, all other filtration types appear to have relatively the same impact on reducing
particles over time. The 0.05tm and 0.10pm filters exhibit less variability in lowering the
particle counts which may also be evidence of an optimal filter pore range. It is also important to
note that the MFI particle count data is an order of magnitude higher than that collected from
LO.
A one-way analysis of variance of cumulative particles by filtration type was completed at each
time point. The results are summarized in the table below.
Time 1 2 3 4
P value 0.5187 0.335 0.1424 0.4843
Table 12: Analysis of Variance Using MFI
Again, each of the P values is considered insignificant and could easily be this large by
happenstance. More data might help to determine significance. Similar to LO, additional
statistical analyses were completed to understand the significance of the data and are also
included in the appendix.
5.2.4.2. Visible Inspection
Visual inspection is a subjective test and difficult to maintain consistency even for a single
inspector let alone the possibility of inspector to inspector variation. The descriptions of
particulate matter were collected and the results divided into fibrous and round particles. Despite
efforts to provide a clean environment free of foreign particles, the process development lab and
pilot plant fill finish conditions are not maintained to manufacturing standards and therefore it is
not possible to guarantee a particle free environment during experimentation. If the inspector
was able to quantify the number of particles, the total number was included in the data set. If a
particle was considered "foreign" by the inspector, the counts were not included in the data
defined to detect protein particles. However, fluctuations in the data suggest that particles could
have been counted as both foreign and proteinacious depending on the day of inspection. For
this reason, it is both difficult and somewhat unreliable to quantify the data. The number of
particles (round and fibrous) were summed and averaged across filtration types for each time
interval after filtration.
Visible Fiber - Average Particle Counts
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Figure 20: Average Visible Fibrous Particles
Figure 20 above displays the average number of fiber-like particles in each filtration group over
time. Each number on the X axis represents an inspection point in days after filtration. Because
the samples were controlled (never opened after transfer into vials), the observed variability can
be attributed to the inspector and the behavior of the particles. The numbers do, however,
remain relatively low and the particles show no significant increases over time. Contrasting with
the data from the subvisible detection, the highest visible fiber-like particle counts are seen in the
0.02pm, 0.05pm and 0.10tpm filters and the lowest counts are seen in the Control and 0.22ipm in
series. However, because these fiber particles are very low overall, the presence of a single
foreign fiber counted as a proteinacious particle can significantly skew the data. A similar
problem is seen when quantifying the visible round particles with the presence of microbubbles.
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Figure 21: Average Visible Round Particles
Figure 21 shows the number of visible round particles presented in the same way as the fiber-like
particles. Similar to the fiber-like counts, the 0.02pm, 0.05pm and 0.10ipm filters exhibit the
lowest average counts while the Control and 0.22ipm in series are almost always lowest.
However, it is important to note that corresponding to the significant drop in round particles, all
samples are described as having "many microbubbles" present. The particle descriptions
reported abruptly change from "nothing observed" (9/14/07) to "many microbubbles" (9/17/07)
in all of the samples. The presence of microbubbles may significantly inhibit the ability to see
round particles as supported by the maintained drop in round particles 15 days after filtration. It
is not clear what could have caused all of the samples to form "many microbubbles" in the three
days between inspections as inspection conditions were maintained and the samples remained
unopened.
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5.2.4.3. Discussion
This experiment was carried out with the intention of determining the ability of filters with
nominal pore sizes smaller than those currently used in downstream manufacturing purification
to remove or reduce the presence of protein particles both immediately and over time. The data
collected, however, does not appear to make a conclusive argument. SEC shows a <1%
reduction of total aggregate (oligomers) in the 0.02pm filter type. The general SEC trend
suggests that as the pore size decreases, the stress on the protein increases, causing "clippings" or
degradation of the protein creating an abundance of LMW species. The later disappearance of
LMW species might suggest binding to other proteins in solution leading to the possible
formation of particles over time. FFF did not detect a presence of subvisible particles and
showed no difference between the control and other filtration types.
LO and MFI both offer the advantage of detecting particles in the native solution while SEC
HPLC and FFF require diluted material. The LO and MFI measurements suggest that there may
be an optimal range in pore sizes able to reduce larger subvisible particles over time. The
0.05pm and 0.10 m filters appear to consistently maintain low particle counts during the
approximately 160 day period. The MFI shows a similar pattern, however all particle counts
appear to increase at time 4, particularly the 0.02pm filtered samples. The considerable leap in
the number of particles at time 4 of the 0.02pm filtered samples might be indicative of the effects
of filtration stress over time. The current implication of an optimal range of filtration pore size is
unconvincing, but statistical analyses suggest that more data is needed to make more certain
claims. The visual inspection was also inconclusive and seemingly biased by foreign particles
and the belated incidence of microbubbles. Additional tests are needed to determine the
feasibility of particles to remove or reduce proteinacious particles. However, the tests could be
narrowed with the understanding that practical application of the 0.02pm filter to a
manufacturing process would require either a sizeable increase in surface area (to be determined
by additional experimentation) or and an acceptance of significant material loss; either
implication is costly. Even if the filter shows a reduction in particle count, the gained yield
would need to offset the material lost in the production process. Additionally, the 0.22pm in
series filter could be removed from future tests as it appeared to have no positive impact.
6. Conclusions and Recommendations
Amongst the exciting prospects of the biotechnology industry lie equally novel challenges for its
practitioners to address. Unlike other industries, it faces an especially complex product, an
extensive development life cycle and strict regulations that help ensure safety to the patients it
serves. The nature of these three challenges presents the potential for a firm to create a
competitive advantage in the industry. Each challenge is tightly intertwined and their overlap is
suggestive of the need for a holistic approach to address the problem. Thorough characterization
of the product and processes reduces product risk and regulatory pressure. Organizational
optimization reduces the development lifecycle by efficiently sharing knowledge and leveraging
the extensive knowledge base.
Proteinacious particles are an example of one of the new challenges facing the biopharmaceutical
industry. Chapter 2 presented the observation that not only is it unclear how they arise, but their
clinical relevance is not understood and significant gaps exist in the literature correlating side
effects with particle size and number. The ability to generate a thorough understanding of the
product is a function of the tools capable of visualizing the problem. The mechanisms leading to
particles are not entirely understood because it is not possible to track their formation from
monomer to visible particle. Chapter 2 explores the taxonomy, kinetics, measurement and
regulation of protein particles as they are understood today. Although their existence is not
entirely deciphered, their impact on the business is. In addition to increasing the risk of the firm
and the safety of patients, protein particles consume development resources and reduce product
yields which directly impact the bottom line.
There is an assortment of approaches, some more tactical than others, that a practitioner can use
to address protein particles in the overall strategy of the business. Chapter 3 broadly divides
potential approaches into those looking to meet current regulatory requirements and those
looking to influence future regulation. To meet regulatory expectations, a framework is
presented to align functional groups and their processes across the development lifecycle.
Alignment and collaboration are necessary to holistically address the problem and utilize the
resources of the firm. Ongoing research across the firm and academia is presented to briefly
review some of the potential resources. Within this framework, opportunities exist to align
expectations across the functional processes and leverage knowledge generated by both the firm
and academic institutions collectively working to advance science and the industry.
Analytical characterization remains one of the chief bottlenecks in the thorough diagnosis of
protein particles. The purpose of Chapter 4 is to explore the capabilities and limitations of both
current and new innovative technologies to achieve that end. Protein particles exist in a very
dynamic range; this section, however, is focused on subvisible particles that are of the greatest
interest to regulatory bodies. Here, it is suggested that the individual strengths of these
technologies lies in comprehensive and cross validated use.
The further exploration of one tactical approach is the focus of Chapter 5. It is hypothesized that
by changing the manufacturing process to include an additional filtration step, particles and there
nucleating agents may be reduced or removed altogether. In this experiment, a variety of filters
with pore sizes smaller than those currently used at a single purification step are investigated to
achieve particle reduction. Both current and innovative analytical tools are used to measure the
particles initially after filtration and at time intervals covering a five month period. The results
of the experiment suggest that although additional filtration may reduce particles in some
optimal range, it is inconclusive and requires more targeted experimentation. It is important to
recognize that filtration is only one tactical response in which the need for a more proactive
comprehensive answer exists.
The goal of this thesis was to present a framework for biopharmaceutical companies to mitigate
the affect of protein particles. From this paper's perspective, it is in the best interest of the firm
to address both the current regulatory requirements and proactively collaborate within the
industry and with regulatory bodies to change how the problem is thought of in the future. The
answer does not lie within a single segment of science or functional process in the industry and
therefore requires a holistic approach. While this thesis focuses primarily on a specific line of
attack, it is only one piece of the puzzle. As a problem that directly effects the bottom line of a
firm, it is imperative to act strategically through organizational optimization and tactically
through effective experimentation and project execution that will further the body of knowledge.
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Appendix
T=1
Oneway Analysis of Cumulative Particles by Filtration Type
0.02um 0.05um 0.lum 0.2uTm x2 Control
Filtration Type
Oneway Anova Summary of Fit
Rsquare 0.304642
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatioi
Level Number
0.02um
0.05um
0.1um
0.2um x2
Control
DF Sum of Squares
4 142666.10
8 325640.67
12 468306.77
Mean
2 106.000
2 146.000
3 103.000
3 352.000
3 86.333
Std Dev
12.728
38.184
48.877
399.000
20.502
Mean Square
35666.5
40705.1
Std Err Mean
9.00
27.00
28.22
230.36
11.84
F Ratio
0.8762
Lower 95%
-8.4
-197.1
-18.4
-639.2
35.4
Prob > F
0.5187
Upper 95%
220.4
489.1
224.4
1343.2
137.3
T=2
Oneway Analysis of Cumulative Particles By Filtration Tvpe
200-
C,
150-
iL
100-
0.02um 0.05um
Filtration Type
Oneway Anova Summary of Fit
Rsquare
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviations
Level Number
0.02um 2
0.05um 2
0.1um
0.2um x2
Control
3
3
3
DF Sum of Squares
4 10824.744
8 16160.333
12 26985.077
Mean
59.500
65.500
96.333
92.000
141.667
Std Dev
0.7071
23.3345
19.3993
26.2869
82.0995
Mean Square
2706.19
2020.04
Std Err Mean
0.500
16.500
11.200
15.177
47.400
T=3
Oneway Analysis of Cumulative Particles By Filtration Type
0.02um 0.05um 0.1um 0.2um x2 Control
Filtration Type
U
A A ^r-
0.lum 0.2um x2 Control
0.401138
F Ratio
1.3397
Lower 95%
53.1
-144.2
48.1
26.7
-62.3
Prob > F
0.3350
Upper 95%
65.85
275.15
144.52
157.30
345.61
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Oneway Anova Summary of Fit
Rsquare
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatioi
Level Number
0.02um
0.05um
0.1um
0.2um x2
Control
0.539098
DF Sum of Squares
4 21347.603
8 18251.167
12 39598.769
Mean
2 143.500
2 82.000
3 84.000
3 188.000
3 122.333
Std Dev
28.9914
1.4142
26.8514
58.5064
67.5302
Mean Square
5336.90
2281.40
Std Err Mean
20.500
1.000
15.503
33.779
38.989
T=4
Oneway Analysis of Cumulative Particles By Filtration Type
0.02um 0.05um 0.lum 0.2um x2 Control
Filtration Type
Oneway Anova Summary of Fit
Rsquare 0.321611
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatioi
Level
0.02um
0.05um
0.lum
0.2um x2
Control
HIAC
DF Sum of Squares
4 31376.077
8 66183.000
12 97559.077
Number Mean
2 400.500
2 243.500
3 301.667
3 265.667
3 275.667
F Ratio
2.3393
Lower 95%
-117.0
69.3
17.3
42.7
-45.4
Prob > F
0.1424
Upper 95%
403.98
94.71
150.70
333.34
290.09
Mean Square
7844.02
8272.88
Std Err Mean
27.500
23.500
29.384
34.930
92.254
Std Dev
38.891
33.234
50.895
60.501
159.788
F Ratio
0.9482
Lower 95%
51.1
-55.1
175.2
115.4
-121.3
Prob > F
0.4843
Upper 95%
749.92
542.10
428.10
415.96
672.60
__
T=1
Oneway Analysis of Cumulative Particles By Filtration Type
50
30-
10- ANi _-o_:
0.02um 0.05um 0.1um 0.2um x2 Control
Filtration Type
Oneway Anova Summary of Fit
Rsquare
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatiol
Level Number
0.02um 2
0.05um 2
0.1um 3
0.2um x2 3
Control 3
DF Sum of Squares
4 1762.1859
8 1633.5833
12 3395.7692
Mean
7.7500
6.2500
11.6667
12.5000
37.1667
Std Dev
3.8891
5.3033
11.1841
7.4666
24.7857
Mean Square
440.546
204.198
Std Err Mean
2.750
3.750
6.457
4.311
14.310
T=2
Oneway Analysis of Cumulative Particles By Filtration Type
F Ratio
2.1574
Lower 95%
-27.19
-41.40
-16.12
-6.05
-24.40
? U)
E U)a
U
0.02um 0.05um 0.1um 0.2um x2 Control
Filtration Type
- 1
U)
0,
(U
03
0.518936
Prob > F
0.1647
Upper 95%
42.692
53.898
39.449
31.048
98.738
Oneway Anova Summary of Fit
Rsquare
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatiol
Level Number
0.02um 2
0.05um 2
O.1um 3
0.2um x2 3
Control 3
0.235136
DF Sum of Squares
4 10.951923
8 35.625000
12 46.576923
Mean
1.50000
1.75000
1.00000
3.50000
2.50000
Std Dev
0.00000
1.06066
0.50000
4.09268
0.50000
T=3
Oneway Analysis of Cumulative Particles By Filtration Type
0.02um 0.05um 0.1um 0.2um x2 Control
Filtration Type
Oneway Anova Summary of Fit
Rsquare
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatioi
Level
0.02um
0.05um
0.1um
0.2um x2
Control
DF Sum of Squares
4 24.041667
8 42.458333
12 66.500000
Number Mean
2 4.25000
2 3.00000
3 1.66667
3 3.16667
3 5.50000
Std Dev
2.47487
2.12132
0.76376
2.46644
3.04138
Mean Square
2.73798
4.45313
Std Err Mean
0.0000
0.7500
0.2887
2.3629
0.2887
F Ratio
0.6148
Lower 95%
1.500
-7.780
-0.242
-6.667
1.258
Prob > F
0.6641
Upper 95%
1.500
11.280
2.242
13.667
3.742
0.361529
Mean Square
6.01042
5.30729
Std Err Mean
1.7500
1.5000
0.4410
1.4240
1.7559
F Ratio
1.1325
Lower 95%
-17.99
-16.06
-0.23
-2.96
-2.06
Prob > F
0.4065
Upper 95%
26.486
22.059
3.564
9.294
13.055
T=4
Oneway Analysis of Cumulative Particles By Filtration Type
0.02um 0.05um 0.1um 0.2um x2 Control
Filtration Type
Oneway Anova Summary of Fit
Rsquare 0.575171
Analysis of Variance
Source
Filtration Type
Error
C. Total
Means and Std Deviatioi
Level
0.02um
0.05um
0.1um
0.2um x2
Control
DF Sum of Squares
4 652.0673
8 481.6250
12 1133.6923
Number Mean
2 26.5000
2 7.7500
3 7.3333
3 18.1667
3 20.3333
Mean Square
163.017
60.203
Std Err Mean
5.0000
1.7500
0.6009
6.0713
5.8047
Std Dev
7.0711
2.4749
1.0408
10.5159
10.0540
F Ratio
2.7078
Lower 95%
-37.03
-14.49
4.75
-7.96
-4.64
Prob > F
0.1075
Upper 95%
90.031
29.986
9.919
44.290
45.309
